<DOC>
	<DOCNO>NCT02908269</DOCNO>
	<brief_summary>The aim study describe safety immunogenicity 2016-2017 formulation Fluzone Quadrivalent vaccine child 3 &lt; 9 year age adults 18 &lt; 65 year age , 2016-2017 formulation Fluzone High-Dose vaccine adult ≥ 65 year age . Primary Observational Objectives - To describe safety 2016-2017 formulation Fluzone Quadrivalent vaccine child 3 &lt; 9 year age adults 18 &lt; 65 year age , safety 2016-2017 formulation Fluzone High-Dose vaccine adult ≥ 65 year age . Observational Objectives : - To describe immunogenicity 2016-2017 formulation Fluzone Quadrivalent vaccine child 3 &lt; 9 year age adults 18 &lt; 65 year age , immunogenicity 2016-2017 formulation Fluzone High-Dose vaccine adult ≥ 65 year age . - To submit available serum approximately 90 subject ( 30 subject 3 &lt; 9 year age 30 subject 18 &lt; 65 year age receive Fluzone Quadrivalent vaccine , 30 subject ≥ 65 year age receive Fluzone High-Dose vaccine ) CBER analysis WHO , CDC , FDA support formulation recommendation subsequent influenza vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Fluzone® Quadrivalent Fluzone® High-Dose , Influenza Vaccines , 2016-2017 Formulations</brief_title>
	<detailed_description>All participant receive 0.5-mL intramuscular dose assign vaccine Visit 1 . For subject 3 &lt; 9 year age 2 dos influenza vaccine recommend per Advisory Committee Immunization Practices ( ACIP ) guidance , second dose Fluzone Quadrivalent vaccine ( volume ) administer Visit 2 . Participants follow Visit 1 Visit 2 evaluation safety outcome . Solicited adverse event information collect 7 day vaccination . Unsolicited non-serious adverse event ( AEs ) serious adverse event ( SAEs ) collect Visit 1 Visit 2 , Visit 3 subject receive 2 dos study vaccine . Immunogenicity evaluate subject prior vaccination day 0 ( Visit 1 ) day 28 3 &lt; 9 year old 21 day adults 18 year old , follow final vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 3 &lt; 9 year adult age ≥ 18 year day first study vaccination ( study product administration ) . Informed consent form sign dated subject ≥ 18 year age . Assent form sign dated subject 7 &lt; 9 year age , informed consent form ( ICF ) sign date parent ( ) guardian ( ) subject 3 &lt; 9 year age . Subject parent/guardian ( subject 3 &lt; 9 year age ) able attend schedule visit comply trial procedure . Subject pregnant , lactating , childbearing potential use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination . To consider nonchildbearing potential , female must premenarche , postmenopausal least 1 year , surgically sterile . Participation time study enrollment ( 30 day precede first trial vaccination ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure . Receipt vaccine 30 day precede first trial vaccination , plan receipt vaccine Visit 2 subject receive 1 dose influenza vaccine Visit 3 subject receive 2 dos influenza vaccine . Previous vaccination influenza ( 20162017 influenza season ) either trial vaccine another vaccine . Receipt immune globulin , blood , bloodderived product past 3 month . Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) . Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance . Thrombocytopenia , may contraindication intramuscular vaccination , discretion Investigator . Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination . Deprived freedom administrative court order , emergency setting , hospitalize involuntarily . Current alcohol abuse drug addiction . Chronic illness , opinion Investigator , stage might interfere trial conduct completion . Moderate severe acute illness/infection ( accord Investigator judgment ) day plan vaccination febrile illness ( temperature ≥ 100.4°F [ 38.0°C ] ) . A prospective subject include study condition resolve febrile event subside . Identified Investigator employee Investigator study center direct involvement propose study ( subject ≥18 year age ) identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study ( subject ) . History serious adverse reaction influenza vaccine . Personal history GuillainBarré syndrome . Any condition opinion Investigator would pose health risk subject enrol could interfere evaluation vaccine . Personal history clinically significant developmental delay ( discretion Investigator ) , neurologic disorder , seizure disorder . Known seropositivity human immunodeficiency virus , hepatitis B , hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Fluzone® Quadrivalent , Influenza Vaccine ( 2016-2017 formulation )</keyword>
	<keyword>Fluzone® High Dose , Influenza Vaccine ( 2016-2017 formulation )</keyword>
</DOC>